Latest Forum Topics /
EFH Ltd
Last:0.046
-0.003
|
 Post Reply
|
|
BIO PHARMA company do research on MEDICAL DISEASES
|
|||||
|
Trader130
Supreme |
17-Jul-2020 06:44
|
||||
|
x 0
x 0 Alert Admin |
Cheh I tot so confidentl
|
||||
| Useful To Me Not Useful To Me | |||||
|
Trader130
Supreme |
17-Jul-2020 06:41
|
||||
|
x 0
x 0 Alert Admin |
Who is JY ?? Will he make the price go up ? 😂
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Laurenpanna
Veteran |
17-Jul-2020 02:57
|
||||
|
x 1
x 0 Alert Admin |
Hey Brother or Sister, I think you better exit the counter quick. Take cash first. Don' t panic. Cut loss is most important. Because no point giving yourself so much stress. Take the cash and buy other safer ones. For me, I would buy more if it drop tomorrow.
|
||||
| Useful To Me Not Useful To Me | |||||
|
Laurenpanna
Veteran |
17-Jul-2020 02:53
|
||||
|
x 0
x 0 Alert Admin |
Hi Bro.... I am not a stock Guru like some other people here. But in my opinion, good dividend would be banks and REIT. I personally own DBS, OCBC, UOB, as well as HKEX Hang Seng Bang, HSBC, and BOC HK. I think they would bounce back. Dividends are good too (HSCS might stop dividend this year though but it is okay). Personally, for REITS - i am holding some very good ones, AIMS APAC , CMT , CCT, Lendlease, SPHREIT, IREIT Global , Cromwell, Mapletree NACT. I also hold ASCOTT (which i think for now Hospitality might not be doing good, so you may want to think twice). As for the HKEX, i am holding LINK REIT, Sunlight REIT and Prosperity REIT, which i think all are very good. As for ETF, i am holding STI ETF , NIKKO AM SREIT as well as VOO and Vanguard Total China, Tracker HK fund. Which i think is good too . Other dividend stock i am holding, which i think currently is not Doing so well. Such as SATS (This year no more dividend), Comfort Delgro, SBS, but i will HOLD and wait.... I am also Holding Vicom, which is also quite stagnant. I also have SEMPCORP ,desperately waiting for their Demerger hahahah. oh ya and TWO MORE which i am holding that I really like. CSE Global and Netlink Trust --> This two I will definitely Hold as i think they are going to be some Multibagger in months to come.
|
||||
| Useful To Me Not Useful To Me | |||||
|
newbie888
Veteran |
17-Jul-2020 02:28
|
||||
|
x 0
x 0 Alert Admin |
Oo but why vested in cb when you seems not to trust JY.. Esp when the two price is always going in tandem
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
xKaiseRx
Veteran |
17-Jul-2020 01:35
|
||||
|
x 0
x 0 Alert Admin |
scared no time to run nia... did not vested in bio but cb... this guy also in the board ... tooo scary already
|
||||
| Useful To Me Not Useful To Me | |||||
|
xKaiseRx
Veteran |
17-Jul-2020 01:33
|
||||
|
x 0
x 0 Alert Admin |
really like this liao lor
|
||||
| Useful To Me Not Useful To Me | |||||
|
newbie888
Veteran |
17-Jul-2020 01:32
|
||||
|
x 0
x 0 Alert Admin |
Only time can prove itself... You may be right after all?
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
Starship
Supreme |
17-Jul-2020 01:13
|
||||
|
x 0
x 0 Alert Admin |
|
||||
| Useful To Me Not Useful To Me | |||||
|
chikubang
Member |
17-Jul-2020 01:07
|
||||
|
x 0
x 0 Alert Admin |
This is a grant given by A*STAR. And the anouncement didn' t even mention that they have already developed....Need to read the content and not just the headlines. | ||||
| Useful To Me Not Useful To Me | |||||
|
xKaiseRx
Veteran |
17-Jul-2020 01:07
|
||||
|
x 0
x 0 Alert Admin |
he himself dont expect anything to happen... at all
|
||||
| Useful To Me Not Useful To Me | |||||
|
wenyen
Master |
17-Jul-2020 01:04
|
||||
|
x 0
x 0 Alert Admin |
Biolidics response to sgx query
"As described in the Announcement, the Company would like to highlight again that there is no certainty that the Company will be able to, among others, successfully develop the serology tests which incorporate the Technology. The Company would like to highlight that there is no certainty that the Company will be able to, among others, successfully develop, achieve the relevant regulatory authorisations or approvals and commercialise the serology tests which incorporate the Technology, if developed" |
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
xKaiseRx
Veteran |
17-Jul-2020 01:03
|
||||
|
x 0
x 0 Alert Admin |
?quote from army daze?
my grandmother can do better...
unquote
|
||||
| Useful To Me Not Useful To Me | |||||
|
Starship
Supreme |
17-Jul-2020 01:01
|
||||
|
x 0
x 0 Alert Admin |
RESPONSE TO QUERIES BY SGX REGCO ON THE COMPANY&rsquo S ANNOUNCEMENT OF 14 JULY 2020 Company&rsquo s response to Q1: The Company is obliged to pay for the use of the Technology. The terms of such payment are confidential and it is not in the Company' s interest to publicly disclose the same. Company&rsquo s response to Q2: Generally speaking, the Company has the right to use the Technology and develop its own enhancements during the Term. After the Term, the Company will no longer have the right to use the Technology, but will own the enhancements which the Company has created on its own. Company&rsquo s response to Q3(a): The Company is currently in the initial phase of the product development. The Company has shortlisted a number of potential partners for product development, optimisation, validation and eventual commercialisation of the Technology and/or Licensed Products. The Company is still in the process of assessing the potential partners and will make the necessary announcements to update shareholders and potential investors as and when there are material developments. As described in the Announcement, the Company would like to highlight again that there is no certainty that the Company will be able to, among others, successfully develop the serology tests which incorporate the Technology. Company&rsquo s response to Q3(b): Based on the Company' s preliminary assessment, it is anticipated that it would take up to nine months to incorporate the Technology into a serology test kit. Company&rsquo s response to Q3(c): The Company is required to perform validation of the serology tests which incorporate the Technology and obtain the relevant regulatory authorisations and/or approvals before it can commercialise the serology tests (" Regulatory Approvals" ). At this point in time, the Company is not able to provide any indication of the time required for validation to be completed and to obtain the relevant Regulatory Approvals. To clarify, the Company intends to incorporate the Technology into new serology test kits, and not its existing COVID-19 Antibody Test Kit. It is also critical to obtain suitable product liability insurance to ensure the commercial viability of the serology tests prior to commercialisation. The Company would like to highlight that there is no certainty that the Company will be able to, among others, successfully develop, achieve the relevant regulatory authorisations or approvals and commercialise the serology tests which incorporate the Technology, if developed. The Company will make the necessary announcements to update shareholders and potential investors as and when there are material developments. Company&rsquo s response to Q3(d): The commercialisation of the serology tests which incorporate the Technology depends on (i) the time required to obtain the Regulatory Approvals, which is beyond the Company' s control, and (ii) the Company&rsquo s ability to obtain suitable product liability insurance for such serology tests. As such, at this point in time the Company is unable provide any indication on when the Company will be able to market the serology tests which incorporate the Technology, if developed. As clarified above, the Company intends to incorporate the Technology into new serology test kits only. The Company will make the necessary announcements to update shareholders and potential investors as and when there are material developments. Company&rsquo s response to Q4: As set out at the Company' s response to Question 3 above, the Company is currently in the initial phase of the product development and has shortlisted a number of potential partners for product development, optimisation, validation and eventual commercialisation of the Technology and/or Licensed Products. The Company is still in the process of assessing the potential partners and will make the necessary announcements to update shareholders and potential investors as and when there are material developments. Company&rsquo s response to Q5(a): As part of good corporate governance and with the intention of actively updating its shareholders of developments during these times of heightened scrutiny on disclosures and price volatility, the Company wishes to keep the market informed of its COVID-19 related activities during this rapidly evolving pandemic situation and hence decided to make the Announcement. The Agreement was signed after trading hours on 9 July 2020. As 10 July 2020 was Polling Day for the Singapore General Election and 11 July 2020 and 12 July 2020 was a weekend, the Company was only able to finalise the contents of the Announcement on 14 July 2020. As set out in the Announcement, the Agreement is not expected to have a material impact on the earnings per share and the net asset value of the Group for the current financial year ending 31 December 2020. The Company had also highlighted that there is no certainty that the Company will be able to, among others, successfully develop the serology tests which incorporate the Technology. The Announcement which would not have a material impact on the current financial year, was disclosed with the intention of keeping the market updated. Company&rsquo s response to Q5(b): The Sponsor was aware and was consulted on the disclosure of this matter. The Sponsor had provided its comments to various drafts of the Announcement and was apprised of the comments on the draft Announcement received from various parties. The Sponsor had also advised the Company to monitor the Company&rsquo s share price and trading activities prior to the release of the Announcement. The Sponsor advised the Company to call for a trading halt on 13 July 2020 after consultation with the SGX-ST. Company&rsquo s response to Q5(c): The Sponsor and the Board approved the Announcement on 14 July 2020, at and around 9.37 p.m. and 10.45 p.m., respectively. BY ORDER OF THE BOARD Yee Pinh Jeremy Non-Executive Non-Independent Chairman 16 July 2020 |
||||
| Useful To Me Not Useful To Me | |||||
|
Lobangtan
Member |
17-Jul-2020 00:58
|
||||
|
x 0
x 0 Alert Admin |
Yap,agree, he does it to other counters too
|
||||
| Useful To Me Not Useful To Me | |||||
|
Starship
Supreme |
17-Jul-2020 00:48
|
||||
|
x 0
x 0 Alert Admin |
Read up the hundreds of very insightful posts in SG' s most followed dividend investor -- AK71 of ASSI. He only writes what he does and why in great detail and logic. He will never advise or tell readers what they shd or must do. His annual dividends alone is in the 6 figures. Very educational and insightful, lots of long-term dividend investors emulate him. http://singaporeanstocksinvestor.blogspot.com
|
||||
| Useful To Me Not Useful To Me | |||||
|
newbie888
Veteran |
17-Jul-2020 00:44
|
||||
|
x 0
x 0 Alert Admin |
Each to his own bro.. Demeaning other counters to see others in misery maybe his hobby.. Chillax.. Lol..
|
||||
| Useful To Me Not Useful To Me | |||||
|
Starship
Supreme |
17-Jul-2020 00:42
|
||||
|
x 0
x 0 Alert Admin |
|
||||
| Useful To Me Not Useful To Me | |||||
|
newbie888
Veteran |
17-Jul-2020 00:41
|
||||
|
x 0
x 0 Alert Admin |
On a serious note, I'm looking to be vested in dividend stocks too. Any to recommend?
|
||||
| Useful To Me Not Useful To Me | |||||
|
Starship
Supreme |
17-Jul-2020 00:38
|
||||
|
x 0
x 0 Alert Admin |
How can I be a stock guru when don' t trade. The stocks I invest are for their good dividends and for long-term holding. Don' t need to be a guru to do that.
|
||||
| Useful To Me Not Useful To Me | |||||
